Our investment thesis is driven by key worldwide trends, including:
A growing population of 65 years of age and older. By 2060:
Tremendous pressure on all governmental and private healthcare spending. By 2020:
A steady increase in chronic diseases: By 2020:
As a result, there is a global and universal need to deliver more healthcare to more people more efficiently.
This efficiency is more likely to come from the application of technologies developed outside of healthcare and applied in a disruptive fashion, than from new therapeutic drugs. BVI has established a superior track record over fifteen years of investing in such disruptive innovation.
Our partners have over 150 years of collective industry experience. This experience allows us to derive most of our investments through direct, personal contacts with:
For many of the companies in which we invest, we are the first, and sometimes the only, institutional investor shown the opportunity based on our hard-earned reputation in the medtech market whereby emerging companies directly seek access to our guidance and capital to achieve “next-level” performance.